Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis

Journal of Renal Care

Volumn 39, Issue 2, 2013, Pages 82-89

  Chennasamudram, Sudha P ^a   Noor, Tanjila ^a   Vasylyeva, Tetyana L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Endothelial function; Inflammation; Peritoneal dialysis; Sevelamer

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; CALCIUM CARBONATE; CHELATING AGENT; CYTOKINE; LIPID; PHOSPHATE; POLYAMINE; SERUM ALBUMIN; SEVELAMER;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERPHOSPHATEMIA; INFLAMMATION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; CROSS-OVER STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHATES; POLYAMINES; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 84878098580     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2013.12009.x     Document Type: Article

References (57)

1. Agarwal R., Debella Y.T., Giduma H.D. et al. (2012). Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. Nephrology Dialysis Transplantation 27, 310-317.
2. Amabile N., Guerin A.P., Tedgui A. et al. (2012). Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrology Dialysis Transplantation 27, 1873-1880.
3. Ates K., Nergizoglu G., Keven K. et al. (2001). Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney International 60, 767-776.
4. Ballou S.P. & Lozanski G. (1992). Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4, 361-368.
5. Block G.A., Hulbert-Shearon T.E., Levin N.W. et al. (1998). Association of serum phosphorus and calcium×phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases 31, 607-617.
6. Bonetti P.O., Pumper G.M., Higano S.T. et al. (2004). Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. Journal of the American College of Cardiology 44, 2137-2141.
7. Caglar K., Yilmaz M.I., Saglam M. et al. (2008). Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clinical Journal of American Society of Nephrology 3, 61-68.
8. Chen F.A., Yang C.Y., Yang W.C. et al. (2012). Ankle-brachial index is a powerful predictor of renal outcome and cardiovascular events in patients with chronic kidney disease. Scientific World Journal 2012, 238494.
9. Chertow G.M., Burke S.K., Dillon M.A. et al. (1999). Long-term effects of sevelamer hydrochloride on the calcium Ã-phosphate product and lipid profile of haemodialysis patients. Nephrology Dialysis Transplantation 14, 2907-2914.
10. Choi H.Y., Lee J.E., Han S.H. et al. (2010). Association of inflammation and protein-energy wasting with endothelial dysfunction in peritoneal dialysis patients. Nephrology Dialysis Transplantation 25, 1266-1271.
11. Cohen D.L. & Townsend R.R. (2011). Should patients with chronic kidney disease have an ambulatory BP monitor for accurate renal and cardiovascular risk assessment? Journal of Clinical Hypertension (Greenwich) 13, 861-862.
12. Demuth K., Blacher J., Guerin A.P. et al. (1998). Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrology Dialysis Transplantation 13, 375-383.
13. Evenepoel P., Selgas R., Caputo F. et al. (2009). Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation 24, 278-285.
14. Fernández M.G., Cerrato O.A., Mondéjar M.J. et al. (2012). Efficacy of dialysis in peritoneal dialysis: utility of bioimpedance to calculate Kt/V and the search for a target Kt. Clinical and Experimental Nephrology 1-7 [Epub ahead of print].
15. Fine A. (2002). Relevance of C-reactive protein levels in peritoneal dialysis patients. Kidney International 61, 615-620.
16. Foley R.N., Parfrey P.S. & Sarnak M.J. (1998). Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Disease 32, S112-S119.
17. Fryirs M., Barter P.J. & Rye K.A. (2009). Cholesterol metabolism and pancreatic beta-cell function. Current Opinion in Lipidology 20, 159-164.
18. Garcia De Vinuesa S., Gomez-Campdera F., Goicoechea M.A. et al. (2005). Risk of cardiovascular disease associated to chronic renal disease. Prevalence and control degree of classical risk factors. Nefrologia 25 (Suppl 4), S18-S22.
19. Goyal R., Faizy A.F., Siddiqui S.S. et al. (2012). Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. North American Journal of Medical Sciences 4, 180-184.
20. Harrison D.G., Armstrong M.L., Freiman P.C. et al. (1987). Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. Journal of Clinical Investigation 80, 1808-1811.
21. Katopodis K.P., Andrikos E.K., Gouva C.D. et al. (2006). Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Peritoneal Dialysis International 26, 320-327.
22. Katsiki N. & Elisaf M. (2011). Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease. Current Medical Research and Opinion 27, 1669-1672.
23. Lei P., Jiang Z., Zhu H. et al. (2012). Poly(ADP-ribose) polymerase-1 in high glucose-induced epithelial-mesenchymal transition during peritoneal fibrosis. International Journal of Molecular Medicine 29, 472-478.
24. Lo W.K., Cheng S.W., Ng S.Y. et al. (2008). Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia. Peritoneal Dialysis International 28, 93-95.
25. London G.M., Guérin A.P., Marchais S.J. et al. (2003). Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation 18, 1731-1740.
26. Luksha L., Stenvinkel P., Hammarqvist F. et al. (2012). Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. PLoS ONE 7, e36056.
27. McIntyre N.J., Fluck R.J., Mcintyre C.W. et al. (2011). Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clinical Journal of American Society of Nephrology 6, 2356-2363.
28. Menon M.K., Naimark D.M., Bargman J.M. et al. (2001). Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrology Dialysis Transplantation 16, 2207-2213.
29. Morgera S., Kuchinke S., Budde K. et al. (1999). Volume stress-induced peritoneal endothelin-1 release in continuous ambulatory peritoneal dialysis. Journal of American Society of Nephrology 10, 2585-2590.
30. Napoli C., De Nigris F. & Palinski W. (2001). Multiple role of reactive oxygen species in the arterial wall. Journal of Cellular Biochemistry 82, 674-682.
31. National Kidney Foundation KDOQI guidelines. (2006). http://www.kidney.org/professionals/kdoqi/guideline_uphd_pd_va/pd_guide3.htm.
32. Navarro-Gonzalez J.F., Mora-Fernandez C., Muros De Fuentes M. et al. (2011). Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of American Society of Nephrology 6, 2272-2279.
33. Nikolov I.G., Joki N., Maizel J. et al. (2006). Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney International 150 Supplement S16-S23.
34. Norhammar A., Malmberg K., Diderholm E. et al. (2004). Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology 43, 585-591.
35. Ohtake T., Kobayashi S., Moriya H. et al. (2005). High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. Journal of the American Society of Nephrology 16, 1141-1148.
36. Paulie S., Perlmann H. & Perlmann P. (2001). Enzyme-Linked Immunosorbent Assay. eLS. Hoboken, NJ, USA: John Wiley & Sons, Ltd.
37. Pecoits-Filho R., Stenvinkel P., Wang A.Y. et al. (2004). Chronic inflammation in peritoneal dialysis: the search for the holy grail? Peritoneal Dialysis International 24, 327-339.
38. Peres A.T., Dalboni M.A., Canziani M.E. et al. (2009). Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International 13, 271-277.
39. Raggi P., Boulay A., Chasan-Taber S. et al. (2002). Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? Journal of the American College of Cardiology 39, 695-701.
40. Ricardo A.C., Lash J.P., Fischer M.J. et al. (2011). Cardiovascular disease among Hispanics and non-Hispanics in the chronic renal insufficiency cohort (CRIC) study. Clinical Journal of the American Society of Nephrology 6, 2121-2131.
41. Samouilidou E.C., Karpouza A.P., Kostopoulos V. et al. (2012). Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Renal Failure 34, 160-164.
42. Smirnov A.V., Volkov M.M., Dobronravov V.A. et al. (2010). Phosphorus and calcium metabolism and the cardiovascular system status in patients with early-stage chronic renal disease. Ter Arkh 82, 25-28.
43. Spaia S. (2011). Phosphate binders: sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia 15, 22-26.
44. St. Peter W.L., Fan Q., Weinhandl E. et al. (2009). Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for medicare & medicaid services data. Clinical Journal of the American Society of Nephrology 4, 1954-1961.
45. Stenvinkel P., Chung S.H., Heimburger O. et al. (2001). Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Peritoneal Dialysis International 21, S157-S162.
46. Taylor M.J., Elgazzar H.A., Chaplin S. et al. (2008). An economic evaluation of sevelamer in patients new to dialysis. Current Medical Research and Opinion 24(2), 601-608.
47. Thambyrajah J., Landray M.J., Mcglynn F.J. et al. (2000). Abnormalities of endothelial function in patients with predialysis renal failure. Heart 83, 205-209.
48. Wang A.Y.-M. (2011). Consequences of chronic inflammation in peritoneal dialysis. Seminars in Nephrology 31, 159-171.
49. Wang A.Y.-M., Wang M., Woo J. et al. (2002). A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney International 62, 639-647.
50. Weir M.A. Jain A.K., Gomes T. et al. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: an analysis of 5, 495 patients receiving maintenance dialysis in Ontario, Canada. American Journal of Kidney Diseases 57, 357-359.
51. Wilkes B.M., Reiner D., Kern M. et al. (1998). Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clinical Nephrology 50, 381-386.
52. Wilson P.W.F. & Meigs J.B. (2008). Cardiometabolic risk: a Framingham perspective. International Journal of Obesity 32, S17-S20.
53. Yamada K., Fujimoto S., Tokura T. et al. (2005). Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Renal Failure 27, 361-365.
54. Yilmaz M.I., Sonmez A., Saglam M. et al. (2012). Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. American Journal of Kidney Disease 59, 177-185.
55. Youming P., Hong L., Fuyou L. et al. (2008). Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients. Nephrology 13, 579-586.
56. Zafeiropoulou K., Bita T., Polykratis A. et al. (2012). Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells. PLoS ONE 7, e30975.
57. Zile M.R., Baicu C.F. & Gaasch W.H. (2004). Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. New England Journal of Medicine 350, 1953-1959.